For the company’s technology will be used to accelerate the “discovery, development, manufacturing and commercialisation of next-generation, cell-based medicines”.
According to a press release issued Tuesday CRISPR Therapeutics (NASDAQ:CRSP) and its joint-venture with Bayer AG, a company called Casebia Therapeutics, have picked up a licence to use MaxCyte’s technology.
Under the terms of the agreement, CRISPR Therapeutics and Casebia will get non-exclusive commercial-use rights to MaxCyte's cell engineering platform.
With it they plan to develop CRISPR-Cas9-based therapies for blood-related diseases and a rare genetic disorder called severe combined immunodeficiency.
MaxCyte will receive upfront, milestone and sales-based payments from any products its platform helps develop.
"The initiation of this commercial license agreement with CRISPR Therapeutics and Casebia, both leaders in gene editing, marks a very important milestone for MaxCyte in executing our business strategy and demonstrates the value of our platform and our intellectual property, as well as our ability to collaborate effectively with companies commercialising cell therapies," said Doug Doerfler, chief executive of MaxCyte.
A great deal has been talked about CRISPR–Cas9 and the potential to edit faulty genes.
But there are wider applications for the technology as this extract from the journal Nature explained.
“What CRISPR offers, and biologists desire, is specificity: the ability to target and study particular DNA sequences in the vast expanse of a genome,” it said.
“And editing DNA is just one trick that it can be used for. Scientists are hacking the tools so that they can send proteins to precise DNA targets to toggle genes on or off, and even engineer entire biological circuits — with the long-term goal of understanding cellular systems and disease.”